Correlation Between ATyr Pharma and Beam Therapeutics

Can any of the company-specific risk be diversified away by investing in both ATyr Pharma and Beam Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ATyr Pharma and Beam Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ATyr Pharma and Beam Therapeutics, you can compare the effects of market volatilities on ATyr Pharma and Beam Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ATyr Pharma with a short position of Beam Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of ATyr Pharma and Beam Therapeutics.

Diversification Opportunities for ATyr Pharma and Beam Therapeutics

-0.21

Correlation Coefficient

ATyr Pharma  Beam Therapeutics

Very good diversification

The 3 months correlation between ATyr and Beam is -0.21. Overlapping area represents the amount of risk that can be diversified away by holding ATyr Pharma and Beam Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Beam Therapeutics and ATyr Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ATyr Pharma are associated (or correlated) with Beam Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Beam Therapeutics has no effect on the direction of ATyr Pharma i.e., ATyr Pharma and Beam Therapeutics go up and down completely randomly.

Pair Corralation between ATyr Pharma and Beam Therapeutics

Given the investment horizon of 90 days ATyr Pharma is expected to under-perform the Beam Therapeutics. In addition to that, ATyr Pharma is 1.49 times more volatile than Beam Therapeutics. It trades about -0.04 of its total potential returns per unit of risk. Beam Therapeutics is currently generating about 0.01 per unit of volatility. If you would invest  3,871  in Beam Therapeutics on September 19, 2024 and sell it today you would lose (1,013) from holding Beam Therapeutics or give up 26.17% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	73.54%
Values	Daily Returns

ATyr Pharma  vs.  Beam Therapeutics

ATyr Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ATyr Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, ATyr Pharma is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders.

Beam Therapeutics

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Beam Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Beam Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with ATyr Pharma and Beam Therapeutics

The main advantage of trading using opposite ATyr Pharma and Beam Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ATyr Pharma position performs unexpectedly, Beam Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Beam Therapeutics will offset losses from the drop in Beam Therapeutics' long position.

The idea behind ATyr Pharma and Beam Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.